|Chemical and physical data|
|Molar mass||261.36 g/mol|
|3D model (Jmol)|
|(what is this?)|
Ethoheptazine produces similar effects to other opioids, including analgesia, sedation, dizziness and nausea. It was sold by itself as Zactane, and is still available as a combination product with acetylsalicylic acid and meprobamate as Equagesic, which is used for the treatment of conditions where both pain and anxiety are present. It was also investigated for use as an antitussive.
Its no longer sold in the United States however it may be sold again if the law is changed to remove the drug from the CSD. Ethoheptazine is not listed as a controlled substance under the Controlled Substances Act 1970 in the United States. The controlled status (Schedule IV) of Equagesic was due to the meprobamate content. Regulation elsewhere varies. The Canadian Controlled Drugs & Substances act specifically excludes the phenazepine opioids, including proheptazine, from control.
- ES Patent 310184
- Batterman RC, Golbey M, Grossman AJ, Leifer P. Analgesic effectiveness of orally administered ethoheptazine in man. American Journal of the Medical Sciences. 1957 Oct;234(4):413-9.
- Diamond J, Bruce WF, Tyson FT. Synthesis and Properties of the Analgesic DL-α-1,3-dimethyl-4-phenyl-4-propionoxyazacycloheptane (Proheptazine). Journal of Medicinal Chemistry. 1964 Jan;7:57-60.
- Cinelli P, Zucchini M. Current pharmaco-therapeutic possibilities in the treatment of pain. Experiments with ethoeptazine. (Italian). Minerva Medica. 1962 Mar 3;53:637-42.
- Scheiner JJ, Richards DJ. Treatment of musculoskeletal pain and associated anxiety with an ethoheptazine-aspirin-meprobamate combination (equagesic): a controlled study. Current Therapeutic Research, Clinical and Experimental. 1974 Sep;16(9):928-36.
- J Pharmacol Exp Ther November 1979 211:401-408
- PDR 1978, pp 1618
|This analgesic-related article is a stub. You can help Wikipedia by expanding it.|